FI952932A0 - Monomeeriset insuliinianalogivalmisteet - Google Patents

Monomeeriset insuliinianalogivalmisteet

Info

Publication number
FI952932A0
FI952932A0 FI952932A FI952932A FI952932A0 FI 952932 A0 FI952932 A0 FI 952932A0 FI 952932 A FI952932 A FI 952932A FI 952932 A FI952932 A FI 952932A FI 952932 A0 FI952932 A0 FI 952932A0
Authority
FI
Finland
Prior art keywords
monomera
insulin analogue
analogue preparation
preparation
insulin
Prior art date
Application number
FI952932A
Other languages
English (en)
Swedish (sv)
Other versions
FI952932A (fi
FI118208B (fi
Inventor
Felippis Michael Rosario De
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI952932(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI952932A0 publication Critical patent/FI952932A0/fi
Publication of FI952932A publication Critical patent/FI952932A/fi
Application granted granted Critical
Publication of FI118208B publication Critical patent/FI118208B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI952932A 1994-06-16 1995-06-14 Monomeeriset insuliinianalogivalmisteet FI118208B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations
US26063394 1994-06-16

Publications (3)

Publication Number Publication Date
FI952932A0 true FI952932A0 (fi) 1995-06-14
FI952932A FI952932A (fi) 1995-12-17
FI118208B FI118208B (fi) 2007-08-31

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952932A FI118208B (fi) 1994-06-16 1995-06-14 Monomeeriset insuliinianalogivalmisteet

Country Status (37)

Country Link
US (3) US5461031A (fi)
JP (1) JP3812962B2 (fi)
KR (1) KR100386038B1 (fi)
CN (1) CN1145641C (fi)
AT (1) AT408611B (fi)
BE (1) BE1009409A5 (fi)
BR (1) BR9502797A (fi)
CA (1) CA2151564C (fi)
CH (2) CH689934A5 (fi)
CO (1) CO4410204A1 (fi)
CZ (1) CZ294556B6 (fi)
DE (1) DE19521753B4 (fi)
DK (1) DK176213B1 (fi)
ES (1) ES2091728B1 (fi)
FI (1) FI118208B (fi)
FR (1) FR2721215B1 (fi)
GB (1) GB2290294B (fi)
GR (1) GR1002494B (fi)
HU (1) HU218943B (fi)
IE (1) IE68852B1 (fi)
IL (1) IL114153A (fi)
IT (1) IT1276722B1 (fi)
LU (1) LU88627A1 (fi)
MY (1) MY116831A (fi)
NL (2) NL1000565C2 (fi)
NO (1) NO320808B1 (fi)
NZ (1) NZ272360A (fi)
PE (1) PE34496A1 (fi)
PL (1) PL183284B1 (fi)
PT (1) PT101723B (fi)
RO (1) RO115124B1 (fi)
SE (1) SE509295C2 (fi)
SI (1) SI9500199A (fi)
TW (1) TW347334B (fi)
UA (1) UA34468C2 (fi)
YU (1) YU39795A (fi)
ZA (1) ZA954941B (fi)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
RU2182015C2 (ru) * 1996-06-20 2002-05-10 Ново Нордиск А/С ПРЕПАРАТ ИНСУЛИНА, СОДЕРЖАЩИЙ NaCl, ПАРЕНТЕРАЛЬНАЯ ГОТОВАЯ ФОРМА, СПОСОБ ПОВЫШЕНИЯ ХИМИЧЕСКОЙ СТАБИЛЬНОСТИ ПРЕПАРАТА ИНСУЛИНА
DE69829953T2 (de) * 1997-02-07 2006-03-02 Novo Nordisk A/S Kristallisation von proteinen
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AR012894A1 (es) * 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
CO4970769A1 (es) * 1997-10-24 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
NZ526672A (en) * 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CA2528741A1 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
PL1648933T3 (pl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Długo działające pochodne insuliny i związane z tym sposoby
JP4601627B2 (ja) * 2004-01-16 2010-12-22 バイオデル， インコーポレイテッド 舌下薬物送達デバイス
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
PL2319500T3 (pl) * 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7605123B2 (en) 2004-07-19 2009-10-20 Biocon Ltd. Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
ES2774354T3 (es) * 2004-10-05 2020-07-20 Novo Nordisk As Una formulación farmacéutica
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (zh) * 2005-12-14 2008-02-27 浙江大学 人工合成胰岛素模拟肽及其应用
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
CN101062948B (zh) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 单体速效胰岛素及其制法和用途
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
WO2009089181A1 (en) * 2008-01-04 2009-07-16 Blodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
EA027757B1 (ru) * 2009-01-28 2017-08-31 Смартселлз, Инк. Конъюгат для контролируемой доставки инсулина
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
AU2010212794A1 (en) 2009-02-12 2011-08-11 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin- 1 for the treatment of metabolic diseases
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
CN105748402B (zh) * 2010-11-24 2022-06-03 杜雷科特公司 生物可降解的药物递送组合物
CA2824397A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
US9427475B2 (en) 2013-10-04 2016-08-30 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
BR112016013832A2 (pt) * 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
CN106102763A (zh) 2014-01-13 2016-11-09 塞尔玛琳糖尿病有限责任公司 速效胰岛素制剂和药物递送系统
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
TW202140063A (zh) 2020-02-18 2021-11-01 丹麥商諾佛 儂迪克股份有限公司 醫藥配方
EP4126058A1 (en) 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US20230374045A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3880346T2 (de) * 1987-02-25 1993-07-29 Novonordisk As Insulinderivate.
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
ATE176482T1 (de) * 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
KR100386038B1 (ko) 2003-08-27
PT101723B (pt) 1997-02-28
US5461031A (en) 1995-10-24
ES2091728B1 (es) 1998-02-01
GB2290294A (en) 1995-12-20
SE9502168L (sv) 1995-12-17
PE34496A1 (es) 1996-10-01
IL114153A0 (en) 1995-10-31
MY116831A (en) 2004-04-30
NL1004643C2 (nl) 1997-02-12
KR960000923A (ko) 1996-01-25
NL1000565A1 (nl) 1995-12-18
DE19521753B4 (de) 2009-07-23
CZ154395A3 (en) 1996-02-14
SE9502168D0 (sv) 1995-06-14
FR2721215A1 (fr) 1995-12-22
ATA101795A (de) 2001-06-15
US5747642A (en) 1998-05-05
JP3812962B2 (ja) 2006-08-23
ITMI951277A1 (it) 1996-12-14
CA2151564A1 (en) 1995-12-17
RO115124B1 (ro) 1999-11-30
CZ294556B6 (cs) 2005-02-16
IE68852B1 (en) 1996-07-24
HU9501717D0 (en) 1995-08-28
NO320808B1 (no) 2006-01-30
DE19521753A1 (de) 1995-12-21
CA2151564C (en) 2003-02-11
NO952356L (no) 1995-12-18
BR9502797A (pt) 1996-03-12
NL1000565C2 (nl) 1996-12-03
HUT71908A (en) 1996-02-28
IT1276722B1 (it) 1997-11-03
UA34468C2 (uk) 2001-03-15
JPH083064A (ja) 1996-01-09
PL183284B1 (pl) 2002-06-28
ITMI951277A0 (it) 1995-06-14
AT408611B (de) 2002-01-25
US5650486A (en) 1997-07-22
TW347334B (en) 1998-12-11
GB9512105D0 (en) 1995-08-09
FI952932A (fi) 1995-12-17
GB2290294B (en) 1999-03-17
BE1009409A5 (fr) 1997-03-04
ES2091728A1 (es) 1996-11-01
FI118208B (fi) 2007-08-31
IE950435A1 (en) 1995-12-27
DK67695A (da) 1995-12-17
CO4410204A1 (es) 1997-01-09
CN1145641C (zh) 2004-04-14
CN1116629A (zh) 1996-02-14
PT101723A (pt) 1995-12-29
CH693019A5 (de) 2003-01-31
CH689934A5 (de) 2000-02-15
HU218943B (hu) 2001-01-29
SI9500199A (en) 1996-02-29
GR1002494B (el) 1996-12-12
FR2721215B1 (fr) 1997-08-14
IL114153A (en) 2000-09-28
NO952356D0 (no) 1995-06-14
YU39795A (sh) 1998-05-15
NL1004643A1 (nl) 1996-12-17
NZ272360A (en) 1997-02-24
LU88627A1 (fr) 1996-02-01
SE509295C2 (sv) 1999-01-11
ZA954941B (en) 1996-12-17
DK176213B1 (da) 2007-02-12
PL309100A1 (en) 1995-12-27

Similar Documents

Publication Publication Date Title
FI952932A0 (fi) Monomeeriset insuliinianalogivalmisteet
FI952931A0 (fi) Insuliinianalogiformulaatioita
NO964106D0 (no) Spröyte
FI971279A (fi) Lääkkeitä
DE69510024D1 (de) Spritze
EE9600122A (et) Infuuser
DE69527782D1 (de) Reibungsfreie spritze
KR920017793U (ko) 드로우어웨이 팁
BR9508339A (pt) Medicamento
DE69521906D1 (de) Zahnhygiene - präparate
BR9503004A (pt) Conjunto de seringa
DE69522857D1 (de) Insulinstandardlösung
FI951155A0 (fi) Farmaseuttinen valmiste
DK137191A (da) Insulinpraeparat
ATA194094A (de) Artikulator
DE69521768D1 (de) Zahnärztliche Spritze
DK88093D0 (da) Stabilt praeparat
KR950022733U (ko) 세척기
DK103393D0 (da) Praeparat
KR950026744U (ko) 주사기
KR960016384U (ko) 주사기
SE9403012D0 (sv) Preparation
NO942021D0 (no) Tannstikker
SE9302099L (sv) Kanylprotes
FI1750U1 (fi) Stol

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118208

Country of ref document: FI

MA Patent expired